Get access

Safety Profile of Treatment in Diabetic Peripheral Neuropathic Pain

Authors


Jessica Robinson-Papp, MD, Mount Sinai School of Medicine, New York, NY, USA. Tel: 212 241-8390; Fax: 212-987-3301; E-mail: Jessica.robinson-papp@mssm.edu.

ABSTRACT

New treatment options for diabetic peripheral neuropathic pain (DPNP) have recently been developed, including two Food and Drug Administration (FDA) approved agents, duloxetine and pregabalin. As clinicians face a broader spectrum of efficacious treatments, side-effect profiles play an increasingly important role in the development of a pain management regimen. In this article we review the safety profile of agents commonly used in the treatment of DPNP.

Ancillary